CYP2D6 Activity Is Correlated with Changes in Plasma Concentrations of Taurocholic Acid during Pregnancy and Postpartum in CYP2D6 Extensive MetabolizersS

被引:2
|
作者
Czuba, Lindsay C. [1 ]
Malhotra, Karan [2 ]
Enthoven, Luke [2 ]
Fay, Emily E. [3 ]
Moreni, Sue L. [3 ]
Mao, Jennie [3 ]
Shi, Yuanyuan [4 ]
Huang, Weize [1 ]
Totah, Rheem A. [4 ]
Isoherranen, Nina [1 ]
Hebert, Mary F. [2 ,3 ,5 ,6 ]
机构
[1] Univ Washington, Sch Pharm, Dept Pharmaceut, Seattle, WA USA
[2] Univ Washington, Sch Pharm, Dept Pharm, Seattle, WA USA
[3] Univ Washington, Sch Med, Dept Obstet & Gynecol, Seattle, WA USA
[4] Univ Washington, Sch Pharm, Dept Med Chem, Seattle, WA USA
[5] Univ Washington, Dept Pharm, Pharm, H-375 Hlth Sci Ctr,1959 NE Pacific St,POB 357630, Seattle, WA 98195 USA
[6] Univ Washington, Dept Pharm, Obstet & Gynecol, H-375 Hlth Sci Ctr,1959 NE Pacific St,POB 357630, Seattle, WA 98195 USA
基金
美国国家卫生研究院;
关键词
SMALL HETERODIMER PARTNER; BILE-ACID; AMINO-ACID; EXPRESSION; FXR;
D O I
10.1124/dmd.123.001358
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Cytochrome P450 2D6 (CYP2D6) is involved in the metabolism of > 20% of marketed drugs. CYP2D6 expression and activity exhibit high interindividual variability and is induced during pregnancy. The farnesoid X receptor (FXR) is a transcriptional regulator of CYP2D6 that is activated by bile acids. In pregnancy, elevated plasma bile acid concentrations are associated with maternal and fetal risks. However, modest changes in bile acid concentrations may occur during healthy pregnancy thereby altering FXR signaling. A previous study demonstrated that hepatic tissue concentrations of bile acids positively correlated with the hepatic mRNA expression of CYP2D6. This study sought to characterize the plasma bile acid metabolome in healthy women (n=47) during mid-pregnancy (25-28 weeks gestation) and {greater than or equal to} 3 months postpartum, and to determine if plasma bile acids correlate with CYP2D6 activity. It is hypothesized that during pregnancy plasma bile acids would favor less hydrophobic bile acids (cholic acid vs. chenodeoxycholic acid), and that plasma concentrations of cholic acid and its conjugates would positively correlate with the urinary ratio of dextrorphan / dextromethorphan. At 25-28 weeks gestation, taurine conjugated bile acids comprised 23% of the quantified serum bile acids compared to 7% {greater than or equal to} 3 months postpartum. Taurocholic acid positively associated with the urinary ratio of dextrorphan / dextromethorphan, a biomarker of CYP2D6 activity. Collectively, these results confirm that the bile acid plasma metabolome differs between pregnancy and postpartum and provide evidence that taurocholic acid may impact CYP2D6 activity during pregnancy.
引用
收藏
页码:1474 / 1482
页数:9
相关论文
共 50 条
  • [41] CYP2D6 genotyping and codeine
    De Leon, Jose
    PEDIATRIC ANESTHESIA, 2008, 18 (03) : 274 - 275
  • [42] CYP2D6 phenotyping with dextromethorphan
    Wojtczak, Anna
    Rychlik-Sych, Mariola
    Krochmalska-Ulacha, Eliza
    Skretkowicz, Jadwiga
    PHARMACOLOGICAL REPORTS, 2007, 59 (06) : 734 - 738
  • [43] Pharmacokinetics of tramadol in CYP2D6 extensive and poor metabolizers
    Pedersen, RS
    Damkier, P
    Brosen, K
    DRUG METABOLISM REVIEWS, 2005, 37 : 63 - 64
  • [44] PharmVar GeneFocus: CYP2D6
    Nofziger, Charity
    Turner, Amy J.
    Sangkuhl, Katrin
    Whirl-Carrillo, Michelle
    Agundez, Jose A. G.
    Black, John L.
    Dunnenberger, Henry M.
    Ruano, Gualberto
    Kennedy, Martin A.
    Phillips, Michael S.
    Hachad, Houda
    Klein, Teri E.
    Gaedigk, Andrea
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2020, 107 (01) : 154 - 170
  • [45] Bupropion plasma levels and CYP2D6 phenotype
    Pollock, BG
    Sweet, RA
    Kirshner, M
    Reynolds, CF
    THERAPEUTIC DRUG MONITORING, 1996, 18 (05) : 581 - 585
  • [46] Use of CYP2D6 Inhibitors with CYP2D6 Opioids: Association with Emergency Department Visits for Pain
    Nahid, Noor Ahmed
    McDonough, Caitrin W.
    Wei, Yu-Jung Jenny
    Cicali, Emily J.
    Gong, Yan
    Fillingim, Roger B.
    Johnson, Julie A.
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2024, 116 (04) : 1005 - 1012
  • [47] Doxepin inhibits CYP2D6 activity in vivo
    Szewczuk-Boguslawska, M
    Kiejna, A
    Beszlej, JA
    Orzechowska-Juzwenko, K
    Milejski, P
    POLISH JOURNAL OF PHARMACOLOGY, 2004, 56 (04): : 491 - 494
  • [48] Assessment of CYP2D6 activity in depressed patients
    Szewczuk-Bogusawska, M
    Orzechowska-Juzwenko, K
    Milejski, P
    Beszlej, JA
    Grzesiak, M
    Kiejna, A
    EUROPEAN NEUROPSYCHOPHARMACOLOGY, 2002, 12 : S219 - S219
  • [49] The decreased in vivo clearance of CYP2D6 substrates by CYP2D6*10 might be caused not only by the low-expression but also by low affinity of CYP2D6
    Fukuda, T
    Nishida, Y
    Imaoka, S
    Hiroi, T
    Naohara, M
    Funae, Y
    Azuma, J
    ARCHIVES OF BIOCHEMISTRY AND BIOPHYSICS, 2000, 380 (02) : 303 - 308
  • [50] Pharmacokinetics of venlafaxine in subjects with extensive or poor CYP2D6 activity.
    Turgeon, J
    Lessard, E
    Yessine, MA
    Hamelin, BA
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 1999, 65 (02) : 171 - 171